Conversational agents reduced depression symptoms in 28,071 adults across 48 randomized trials, with a small-to-moderate effect size (SMD -0.27); they also reduced anxiety (SMD -0.20) and stress (SMD -0.26). This systematic review and meta-analysis found stronger effects in clinical populations and in shorter-duration interventions.

Why It Matters To Your Practice

• Conversational agents may offer a scalable option when access to psychotherapy or follow-up is limited.

• The evidence suggests benefit across multiple symptom domains, not just depression.

• These tools may be especially relevant for patients facing long waits, workforce shortages, or barriers to in-person care.

Clinical Implications

• Consider conversational agents as an adjunct, not a replacement, for standard mental health care.

• Patients with clinical-level symptoms may derive greater benefit than general-population users.

• Shorter interventions appeared more effective, which may favor brief, structured deployment in practice.

Insights

• The review included both AI-based and rule-based conversational agents, so benefits were not limited to one technical approach.

• Robust variance estimation produced results consistent with random-effects modeling, supporting the stability of the findings.

• Risk of bias was largely low, with some concerns related to missing data or selective reporting; publication bias was negligible.

The Bottom Line

• Conversational agents can modestly reduce depression, anxiety, and stress symptoms at scale.

• For clinicians, the near-term opportunity is supervised integration into stepped care, especially where access gaps are greatest.

• Key unanswered questions are durability, patient selection, and how best to embed these tools into routine mental health workflows.